Accelrys Announces Multidisciplinary ELN Supporting Analytical, Process and Formulation Scientists in Drug Development
Complete the form below to unlock access to ALL audio articles.
Accelrys, Inc., has announced the availability of Symyx Notebook by Accelrys v. 6.6 as a multidisciplinary electronic lab notebook (ELN) supporting analytical, process and formulation scientists working in the chemistry, manufacturing and controls (CMC) area of drug development.
The multidisciplinary Symyx Notebook by Accelrys enables cross-disciplinary teams to collaborate more effectively in moving therapeutic substances and related information from research through development to early manufacturing using efficient, validated and compliant processes.
With no custom coding required, the notebook offers out-of-the-box capabilities supporting analytical, process and formulation teams working in small and large molecule development.
"The increasing diversity and complexity of product pipelines and delivery methods in pharmaceutical development today is demanding that organizations do a better job harmonizing processes, corporate ontology, data access and knowledge capture across the R&D continuum," said Accelrys Vice President and Chief Science Officer Dr. Frank Brown.
Brown continued, "Harmonizing processes and data across pharmaceutical development streamlines technology transfer, accelerates drug products to clinical trials and improves the success rate of regulatory dossier submittals."
Integration of Symyx Notebook by Accelrys with existing laboratory information management systems (LIMS), scientific data management systems (SDMS), chromatography data systems (CDS) and other lab informatics solutions optimizes IP collection and transfer between scientific domains by ensuring consistent, accurate information storage and data processing.
For example, integration between Symyx Notebook by Accelrys and Thermo Scientific Watson LIMS enables scientists to electronically pass bio-analytical testing results, sample lists, drug metabolism/pharmacokinetics studies and reports between the ELN and the LIMS. This reduces time-consuming manual transcription and data manipulation errors that can cause regulatory compliance issues.
